<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Coronary artery disease in rheumatoid arthritis: Pathogenesis, risk factors, clinical manifestations, and diagnostic implications
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Coronary artery disease in rheumatoid arthritis: Pathogenesis, risk factors, clinical manifestations, and diagnostic implications
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Coronary artery disease in rheumatoid arthritis: Pathogenesis, risk factors, clinical manifestations, and diagnostic implications
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katherine P Liao, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James R O'Dell, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 25, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of atherosclerotic coronary artery disease (CAD) is increased in patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) or systemic lupus erythematosus.
        </p>
        <p>
         The epidemiologic evidence, possible pathogenetic mechanisms, and clinical relevance of CAD in RA will be reviewed here. The impact of CAD on the management of RA; other cardiac manifestations of RA, including pericarditis, myocarditis, atrioventricular block, valvular regurgitation, embolic events, and rheumatoid nodules; and the general clinical manifestations of RA are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7492.html" rel="external">
          "Coronary artery disease in rheumatoid arthritis: Implications for prevention and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7511.html" rel="external">
          "Overview of the systemic and nonarticular manifestations of rheumatoid arthritis", section on 'Cardiac disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7502.html" rel="external">
          "Clinical manifestations of rheumatoid arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7523.html" rel="external">
          "Rheumatoid nodules", section on 'Cardiac nodules'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         An increased risk of premature death is observed in patients with rheumatoid arthritis (RA). This is largely due to cardiovascular disease, particularly coronary artery disease (CAD). (See
         <a class="medical medical_review" href="/z/d/html/7505.html" rel="external">
          "Disease outcome and functional capacity in rheumatoid arthritis", section on 'Impact of comorbidities'
         </a>
         .)
        </p>
        <p>
         The reported incidence and prevalence of CAD in patients with RA varies based upon the specific manifestations of the disease, the population evaluated, and/or the screening and diagnostic methods utilized [
         <a href="#rid1">
          1-7
         </a>
         ]. A meta-analysis of 24 observational studies comprising 111,758 patients concluded that the risk of CAD mortality was 59 percent higher in patients with RA than in the general population [
         <a href="#rid8">
          8
         </a>
         ]. Risk may be increased once symptoms develop and before patients meet formal classification criteria for the diagnosis of RA [
         <a href="#rid9">
          9-11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many of the underlying mechanisms of pathogenesis of atherosclerosis are shared in patients with and without rheumatoid arthritis (RA). Among the general population, it is increasingly clear that inflammation has a significant role in the development of coronary artery disease (CAD) and that the innate and adaptive immune systems play an important role in the initiation and progression of atherosclerosis.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Inflammation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The results of a number of studies are consistent with the notion that inflammation plays an important role in myocardial infarction (MI) among patients with RA.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inflammation causes accelerated atherosclerosis
         </strong>
         – It is postulated that, in patients with RA, chronic inflammation may accelerate the progression of atherosclerosis, perhaps via the effects of cytokines; abnormal effector functions of T lymphocytes, macrophages, and dendritic cells; immune complexes; coagulation abnormalities; oxidative stress; or a combination of these factors. Some of these mechanisms may be [
         <a href="#rid12">
          12-19
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Changes in the endothelium associated with circulating immune complexes and cytokines.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Direct vascular injury, with depletion of circulating endothelial cell progenitors [
         <a href="#rid15">
          15,20,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A hypercoagulable state due to increased plasma levels of fibrinogen, von Willebrand factor, plasminogen activator inhibitor-1, and/or other acute phase reactants (eg, C-reactive protein [CRP]) that correlate with the erythrocyte sedimentation rate (ESR).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Inflammation in the synovium, which is also occurring in the vascular wall [
         <a href="#rid22">
          22
         </a>
         ], with the strongest association among anti-citrullinated protein antibody (ACPA)-positive patients with RA [
         <a href="#rid23">
          23
         </a>
         ]. Abnormal adaptive immune responses, which involve T cells and dendritic cells, have been described for the inflamed atherosclerotic plaque; these abnormalities are similar to those encountered in the inflamed synovial membrane [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Autoantibodies to oxidized low-density lipoprotein (anti-oxLDL) have also been proposed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         That inflammation plays an important role in MI among patients with RA is also supported by an autopsy study that compared coronary artery pathology of 41 deaths among patients with RA with 82 controls. Less atherosclerosis was present in those with RA, but more inflammation and unstable plaque were noted in those with RA versus the controls [
         <a href="#rid26">
          26
         </a>
         ]. These findings are also consistent with the observation that elevated levels of tumor necrosis factor (TNF)-alpha and interleukin 6 (IL-6) in patients with RA were associated with the severity of subclinical atherosclerosis as measured by coronary artery calcification, and were independent of the Framingham risk score and diabetes mellitus [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inflammation causes hyperglycemia
         </strong>
         – Inflammation may worsen insulin resistance and impair pancreatic beta cell function [
         <a href="#rid27">
          27,28
         </a>
         ]. These metabolic changes may contribute to accelerated atherosclerosis and to the higher incidence of ischemic heart disease characteristic of patients with diabetes mellitus (see
         <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">
          "Overview of established risk factors for cardiovascular disease", section on 'Diabetes mellitus'
         </a>
         ). Additionally, coronary microvascular dysfunction, a manifestation of endothelial dysfunction, was associated with similar risk of mortality in RA as in patients with diabetes [
         <a href="#rid29">
          29
         </a>
         ]. The constellation of abdominal obesity, hyperglycemia, dyslipidemia, and hypertension (referred to variously as the metabolic syndrome, syndrome X, and "the deadly quartet") is associated with a higher risk of CAD and of cardiovascular morbidity and mortality (see
         <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">
          "Metabolic syndrome (insulin resistance syndrome or syndrome X)"
         </a>
         ). The prevalence of the metabolic syndrome may be increased in patients with RA. This was illustrated in a study of 88 patients with early RA, 66 with longstanding RA, and 85 controls [
         <a href="#rid30">
          30,31
         </a>
         ]. The metabolic syndrome was present in 31 percent of patients with early RA, in 42 percent of those with longstanding RA, and in 11 percent of controls. In addition, those with the metabolic syndrome were more likely to have higher coronary calcification scores as detected by computed tomography (CT).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Vasculitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coronary arteritis is a rare complication of rheumatoid vasculitis and is unlikely to be the cause of MI in the absence of other organ involvement. (See
         <a class="medical medical_review" href="/z/d/html/8243.html" rel="external">
          "Etiology and pathogenesis of rheumatoid vasculitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8237.html" rel="external">
          "Clinical manifestations and diagnosis of rheumatoid vasculitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          RISK FACTORS
         </span>
        </p>
        <p class="headingAnchor" id="H3219759444">
         <span class="h2">
          Traditional risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Traditional risk factors for coronary artery disease (CAD) in the general population include hypertension, cigarette smoking, diabetes, older age, and dyslipidemia. One study suggests that, with the exception of former cigarette smoking, these risk factors are not more prevalent in women with rheumatoid arthritis (RA) than in women without RA. This was best shown in an analysis of the Nurses' Health Study in which the clinical risk factors for cardiovascular disease were compared in women with and without RA [
         <a href="#rid32">
          32
         </a>
         ]. No significant differences between the two groups were observed for diabetes, hypertension, concurrent smoking, or dyslipidemia.
        </p>
        <p>
         In studies that included both males and females, differences have been reported in the prevalence of hypertension, diabetes, and dyslipidemia between RA and the general population, although the evidence is conflicting [
         <a href="#rid33">
          33
         </a>
         ]. Other studies noted an increased prevalence of traditional risk factors in patients with RA, particularly in those with longstanding disease [
         <a href="#rid31">
          31,34
         </a>
         ]. These data suggest that traditional risk factors do play a role, but may only explain a small portion of the increased risk of cardiovascular morbidity and mortality in RA.
        </p>
        <p>
         Exercise of even moderate degree has a protective effect against coronary heart disease and all-cause mortality. For a variety of reasons, many patients with RA exercise less than recommended amounts, thereby possibly enhancing the risk of heart disease. As an example, a study of 298 Swedish patients with RA identified 47 percent whose physical activity did not comply with public health recommendations [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Markers of increased systemic inflammation are also associated with an increased risk of CAD. The best studied of these markers in the general population and in those with RA is the acute phase reactant C-reactive protein (CRP). In the Nurses' Health Study, for example, CRP levels were significantly higher in women with RA and heart disease versus those with heart disease but without RA (average CRP levels of 0.87 versus 0.34 mg/dL, respectively) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H759955701">
         <span class="h2">
          Risk factors specific to rheumatoid arthritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are many other factors that may be associated with an increased risk of atherosclerosis in the general population. A few of these have also been evaluated in patients with RA. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with RA appear to have a significantly greater burden of atherosclerotic carotid plaques, suggesting the presence of generalized atherosclerosis [
         <a href="#rid5">
          5,36
         </a>
         ]. The prevalence of carotid plaques as detected ultrasonographically correlates with the duration of RA [
         <a href="#rid3">
          3,36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conflicting data exist concerning an increase in arterial intima-media thickness in patients with RA [
         <a href="#rid5">
          5,36,37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16307.html" rel="external">
          "Overview of possible risk factors for cardiovascular disease", section on 'Arterial intima-media thickness'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coronary artery calcification noted on ultrafast CT scanning, a finding that is correlated with an increased risk of clinical and angiographic coronary atherosclerosis, is more prevalent in patients with established RA than in patients with early RA or healthy controls [
         <a href="#rid31">
          31,38,39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5297.html" rel="external">
          "Coronary artery calcium scoring (CAC): Overview and clinical utilization"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glucocorticoid use is associated with increased cardiovascular risk in patients with RA, with use of higher doses being associated with greater risk [
         <a href="#rid40">
          40,41
         </a>
         ]. This effect appears to be more pronounced among rheumatoid factor-positive RA patients. In a study of 603 adults with RA, those with rheumatoid factors receiving glucocorticoids appeared to be at greater risk for cardiovascular events than those patients who were seronegative [
         <a href="#rid42">
          42
         </a>
         ]. The mechanism of this effect is unknown. Others have proposed that the administration of glucocorticoids increases the risk of CAD via its effects on lipoprotein levels. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic use of selective cyclooxygenase 2 (COX-2) inhibitors and nonselective nonsteroidal antiinflammatory drugs (NSAIDs) may increase the risk of myocardial infarction (MI), stroke, and sudden cardiac deaths. The adverse cardiovascular effects of COX-2 selective inhibitors and NSAIDs are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7968.html" rel="external">
          "NSAIDs: Adverse cardiovascular effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The function of high-density lipoprotein (HDL) as an antiatherogenic particle is impaired or altered. A form of HDL cholesterol that is not protective against cardiovascular disease may be found in some patients with RA [
         <a href="#rid43">
          43,44
         </a>
         ]. HDL with proinflammatory activity in vitro is found in patients with coronary heart disease and elevated HDL levels and is increased in patients with RA compared with healthy controls [
         <a href="#rid43">
          43
         </a>
         ]. In a cross-sectional observational study, this form of HDL was significantly associated with active disease and joint injury in patients with RA and was inversely associated with use of
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         [
         <a href="#rid44">
          44
         </a>
         ]. Furthermore, the ability of HDL to extract cholesterol from lipid-laden atherosclerotic plaques is impaired in patients with active RA and improves when inflammation is reduced [
         <a href="#rid45">
          45,46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4565.html" rel="external">
          "Lipoprotein classification, metabolism, and role in atherosclerosis", section on 'High-density lipoprotein'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is mounting evidence that RA patients with the lowest low-density lipoproteins (LDL) cholesterol levels have higher cardiovascular risk than those with moderate LDL cholesterol levels (generally &lt;160 mg/dL) [
         <a href="#rid47">
          47-49
         </a>
         ]. In line with these findings, a pooled cohort study of RA patients observed that coronary artery calcium (CAC) scores were highest among patients with LDL cholesterol &lt;70 mg/dL [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Triglycerides may be particularly important to the pathogenesis of cardiovascular disease among patients with RA. In a nationwide, population-based cohort study of 15,126 statin-naïve patients with RA in Korea, the risk of major adverse cardiovascular events was higher among patients with the highest baseline triglyceride levels (≥149 mg/dL) compared with patients with the lowest triglyceride levels (≤72 mg/dL; adjusted hazard ratio [HR] 1.74, 95% CI 1.33-2.28) [
         <a href="#rid51">
          51
         </a>
         ]. The same relationship was not seen with LDL cholesterol or total cholesterol in this cohort.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some of the newer antiinflammatory and disease-modifying agents used in patients with RA (eg, the anti-interleukin 6 [IL-6] receptor antibody
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         , Janus kinase [JAK] inhibitors) can change the lipoprotein profile (increase in total cholesterol, triglycerides, LDL, HDL, etc), thus possibly impacting cardiovascular risk adversely. However, the net effect on cardiovascular-related morbidity remains unclear, given the antiinflammatory efficacy of these agents. Findings suggest that the cardiovascular risk may be more strongly related to the treatment rather than changes in lipid levels. A randomized trial compared tocilizumab with
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         , observing higher lipid levels in the tocilizumab arm; the higher lipid levels were not associated with higher risk of cardiovascular events [
         <a href="#rid52">
          52
         </a>
         ].However, a preliminary description of a postmarketing surveillance study comparing
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         with tumor necrosis factor (TNF) inhibitors described a likely increased risk of MI in the tofacitinib arm [
         <a href="#rid53">
          53
         </a>
         ]; the full report with details on lipid levels and cardiovascular events is pending.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1918666636">
         <span class="h3">
          Disease activity and cardiovascular risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is also evidence for an interaction between traditional cardiovascular risk factors and the level of inflammation in RA. In a longitudinal study of 487 patients with RA, a subset of patients experienced rapid progression of carotid intima-media thickness (cIMT), a marker for elevated cardiovascular risk, over a three-year period [
         <a href="#rid54">
          54
         </a>
         ]. As expected, the predictors for rapid cIMT progression included both traditional cardiovascular risk factors and the baseline level of the erythrocyte sedimentation rate (ESR). In addition, there was a significant interaction between the number of cardiovascular risk factors and the ESR, as the risk of rapid progression was higher than would be expected by simply adding the risk from the traditional cardiovascular risk factors to that from the higher levels of inflammation alone. In a separate study, it was estimated that 30 percent of cardiovascular disease events in RA were driven by RA-specific clinical factors, such as disease activity and seropositivity [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Ongoing, persistent disease activity may be necessary to induce acceleration of atherosclerosis. In a study in Northern Sweden involving 79 patients with very early RA and 44 controls, there were no signs of atherosclerosis in patients with newly diagnosed RA when compared with controls, although serum markers suggestive of endothelial activation were significantly elevated in the patients [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         Clinically, persistent disease activity increases cardiovascular events primarily among patients who already have a history of cardiovascular disease. Among patients with RA without prevalent cardiovascular disease, the increase in cardiovascular events can be attributed to traditional cardiovascular risk factors, such as hypertension and hypercholesterolemia [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         In a study from the British Society for Rheumatology Biologics Register (BSRBR), the rates of MI were examined in 8670 RA patients treated with TNF-alpha inhibitors and were compared with the rate of MI among 2170 patients with active RA treated with disease-modifying antirheumatic drugs (DMARDs) [
         <a href="#rid58">
          58
         </a>
         ]. The following findings were observed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Following adjustment for baseline cardiovascular risk factors, there was no reduction in the rate of MI in the TNF inhibitor cohort: incidence rate ratio 1.44 (95% CI 0.56-3.67).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the subset of TNF inhibitor-treated patients who responded to therapy within six months compared with those who did not, MI rates were lower in responders compared with nonresponders (3.5 versus 9.4 MIs per 1000 patient-years).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The adjusted incidence rate ratio for MI in responders versus nonresponders was 0.36 (95% CI 0.19-0.69).
        </p>
        <p>
        </p>
        <p>
         Subsequently, longer-term follow-up data have become available from the BSRBR for Rheumatoid Arthritis, in which it was observed that the reduced risk of MI among patients on TNF inhibitors compared with those using nonbiologic DMARDs remains after adjusting for potential confounders (hazard ratio [HR] 0.61, 95% CI 0.41-0.89) [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H145321565">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations of symptomatic coronary artery disease (CAD) in patients with rheumatoid arthritis (RA) are typically similar to those without RA. However, a larger proportion of patients with RA have clinically silent CAD than do demographically similar individuals in the general population [
         <a href="#rid9">
          9
         </a>
         ]. Patients with RA are also less likely than those without RA to report chest pain during an acute coronary event [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1472.html" rel="external">
          "Approach to the patient with suspected angina pectoris"
         </a>
         .)
        </p>
        <p>
         Patients with RA may experience more severe acute coronary syndromes compared with patients without RA. In a Swedish cohort study involving 1135 patients with RA and acute coronary syndrome identified in a nationwide database, the patients with RA presented more often with sudden cardiac death, ST-segment elevation myocardial infarction (MI), higher levels of troponin, and higher frequencies of inpatient complications, compared with patients in the general population [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
         It is uncertain why patients with RA and CAD are less likely to report chest pain prior to or during a cardiovascular event. Possible explanations are that patients with active arthritis or those with structural joint damage may be less physically active, less likely to place sufficient demand on the heart to elicit angina, and more likely to attribute pain to RA, or it may be that use of nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, or disease-modifying antirheumatic drugs (DMARDs) alters pain perception.
        </p>
        <p class="headingAnchor" id="H145322297">
         <span class="h1">
          DIAGNOSIS AND SCREENING
         </span>
        </p>
        <p class="headingAnchor" id="H145322304">
         <span class="h2">
          Diagnosis of CAD in RA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to the diagnosis of coronary artery disease (CAD) is generally similar in patients with and without rheumatoid arthritis (RA). (See
         <a class="medical medical_review" href="/z/d/html/6832.html" rel="external">
          "Outpatient evaluation of the adult with chest pain"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1534.html" rel="external">
          "Stress testing for the diagnosis of obstructive coronary heart disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/52.html" rel="external">
          "Diagnosis of acute myocardial infarction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H51384270">
         <span class="h2">
          Screening for CAD in RA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the enhanced incidence of CAD in this patient population, we suggest the performance of a yearly cardiovascular evaluation, focused history and physical examination, as well as electrocardiography in patients ≥50 years of age. There should also be a low threshold for proceeding to exercise or pharmacologic stress testing in those with symptoms or electrocardiographic findings suggestive of CAD. (See
         <a class="medical medical_review" href="/z/d/html/1519.html" rel="external">
          "Screening for coronary heart disease"
         </a>
         .)
        </p>
        <p>
         Estimation of cardiovascular risk in patients with RA is described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7492.html" rel="external">
          "Coronary artery disease in rheumatoid arthritis: Implications for prevention and management", section on 'Risk estimation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H145321645">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of chest pain in the general population is broad. This is presented in detail elsewhere.
        </p>
        <p>
         There are some causes of chest pain other than ischemic heart disease that are relatively unique to patients with rheumatoid arthritis (RA). These include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sternoclavicular joint arthritis – Painful sternoclavicular joint involvement with localized tenderness may be present in up to 7 percent of patients with established, generalized RA. Rarely, involvement of the sternoclavicular joint is the initial manifestation of RA. Establishing the diagnosis is usually not difficult, once considered, since point tenderness favors local inflammation. (See
         <a class="medical medical_review" href="/z/d/html/5622.html" rel="external">
          "Major causes of musculoskeletal chest pain in adults", section on 'Rheumatoid arthritis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pericarditis – Acute painful pericarditis occurs in less than 10 percent of patients with RA during their lifetimes. Since small pericardial effusions are relatively common in patients without symptoms of pericarditis, caution is required in attributing chest pain to pericarditis based solely upon echocardiographic findings of an effusion. The major clinical manifestations of acute pericarditis are chest pain, pericardial friction rub, and the classic finding of widespread saddle-shaped or concave-up ST segment elevation on the electrocardiogram (ECG). Increasingly, cardiac magnetic resonance imaging (MRI) is used to identify acute pericardial inflammation [
         <a href="#rid62">
          62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">
          "Acute pericarditis: Clinical presentation and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Herpes zoster – The likelihood of herpes zoster infection is increased in patients with RA receiving immunosuppressive medications, such as biologics,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , or high doses of glucocorticoids. It is characterized by a painful, unilateral vesicular eruption in a restricted dermatomal distribution. The diagnosis may be difficult prior to the appearance of the rash. (See
         <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of herpes zoster"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary hypertension – Exertional chest pain indistinguishable from that of angina pectoris may be a manifestation of pulmonary hypertension, a rare complication of interstitial lung disease in patients with RA. Clinical evidence suggesting right ventricular dysfunction, such as pulmonary artery dilation on plain chest radiography and characteristic echocardiographic findings, may help distinguish chest pain symptoms related to pulmonary hypertension from angina pectoris. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aortitis – Aortitis is a rare complication of RA, which, when present, is typically accompanied by rheumatoid vasculitis in other vessels [
         <a href="#rid63">
          63
         </a>
         ]. Disease at the coronary ostia or associated coronary vasculitis can cause myocardial infarction (MI). Dilatation of the ascending aorta is a common initial finding. Thoracic aortic dissection or rupture could cause chest pain. A "ripping" or "tearing" quality to the pain, associated back pain, pulse deficits, a difference in limb blood pressure of more than 10 mmHg, and hemodynamic compromise are suggestive of aortic dissection. An imaging study such as transthoracic or transesophageal echocardiography, MR angiography, or contrast CT is necessary to confirm the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/8192.html" rel="external">
          "Clinical manifestations and diagnosis of thoracic aortic aneurysm"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest wall pain – Musculoskeletal pain in the chest wall is the most common cause of precordial chest pain in patients with RA and should be considered in the differential diagnosis of the RA patient with chest pain.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H631059551">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116127.html" rel="external">
          "Society guideline links: Rheumatoid arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is an increased incidence of cardiovascular events, including myocardial infarctions (MI) and cardiac deaths, in patients with rheumatoid arthritis (RA) compared with the populations in which they live. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It is postulated that the presence of chronic inflammation in RA may enhance the development of atherosclerosis. This may be the result of effects mediated by cytokines, immune complexes, endothelial dysfunction, or, rarely, coronary vasculitis. Abnormal functions of T cells, dendritic cells, and macrophages have been implicated in promoting inflammation and progression of atherosclerotic plaque formation, and similarities may exist between synovial and vascular inflammation. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The increased risk of coronary artery disease (CAD)-related events does not appear to be mediated entirely through traditional risk factors for atherosclerosis. Use of antiinflammatory drugs such as glucocorticoids, nonsteroidal antiinflammatory drugs (NSAIDs), and cyclooxygenase 2 (COX-2) selective inhibitors may contribute to increased risk for coronary thrombosis. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some medications used in RA can adversely impact the lipoprotein profile, while simultaneously reducing vascular risk surrogates, including inflammatory markers. The net effect on cardiovascular morbidity/mortality may differ by therapy. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Despite an increased incidence of ischemic cardiac events in patients with rheumatoid arthritis (RA), the prevalence of clinical angina pectoris in RA patients is lower than in the general population. Aside from this point, the clinical manifestations and diagnosis of coronary artery disease (CAD) are generally similar in patients with or without RA, but tend to be more severe in the patients with RA. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with RA ≥50 years of age, we suggest yearly history, physical examination, and ECG to periodically assess for the presence of symptomatic CAD or electrocardiographic evidence of a silent MI. Exercise or pharmacologic stress testing is suggested for those with symptoms (eg, angina, atypical chest pain, exertional dyspnea) or electrocardiographic findings suggestive of CAD. (See
         <a class="local">
          'Screening for CAD in RA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As in the general population, the differential diagnosis of chest pain in a patient with RA is broad. Some disorders that may be of particular interest are chest wall pain, pericarditis, Herpes zoster, pulmonary hypertension, and thoracic aortic aneurysm or dissection. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1572165424">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Peter Schur, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004; 63:952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44:2737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107:1303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer LM, Schlienger RG, Matter C, et al. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Juanatey C, Llorca J, Testa A, et al. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003; 82:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006; 65:1608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008; 58:2612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59:1690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kremers HM, Crowson CS, Therneau TM, et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008; 58:2268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmqvist ME, Wedrén S, Jacobsson LT, et al. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum 2009; 60:2861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wållberg-Jonsson S, Cvetkovic JT, Sundqvist KG, et al. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002; 29:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wållberg-Jonsson S, Cederfelt M, Rantapää Dahlqvist S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol 2000; 27:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grisar J, Aletaha D, Steiner CW, et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005; 111:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park YB, Choi HK, Kim MY, et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002; 113:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rho YH, Chung CP, Oeser A, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009; 61:1580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rho YH, Chung CP, Oeser A, et al. Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62:1473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters MJ, van Halm VP, Nurmohamed MT, et al. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J Rheumatol 2008; 35:1495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yiu KH, Wang S, Mok MY, et al. Role of circulating endothelial progenitor cells in patients with rheumatoid arthritis with coronary calcification. J Rheumatol 2010; 37:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wrigley BJ, Lip GY, Shantsila E. Coronary atherosclerosis in rheumatoid arthritis: could endothelial progenitor cells be the missing link? J Rheumatol 2010; 37:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mäki-Petäjä KM, Elkhawad M, Cheriyan J, et al. Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012; 126:2473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geraldino-Pardilla L, Zartoshti A, Bag Ozbek A, et al. Arterial Inflammation Detected With 18 F-Fluorodeoxyglucose-Positron Emission Tomography in Rheumatoid Arthritis. Arthritis Rheumatol 2018; 70:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niessner A, Sato K, Chaikof EL, et al. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 2006; 114:2482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liuzzo G, Goronzy JJ, Yang H, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 101:2883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aubry MC, Maradit-Kremers H, Reinalda MS, et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007; 34:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54:2765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung CP, Oeser A, Solus JF, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008; 58:2105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liao KP, Huang J, He Z, et al. Coronary Microvascular Dysfunction in Rheumatoid Arthritis Compared to Diabetes Mellitus and Association With All-Cause Mortality. Arthritis Care Res (Hoboken) 2021; 73:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung CP, Oeser A, Raggi P, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005; 52:3045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon DH, Curhan GC, Rimm EB, et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50:3444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyer JF, Gourraud PA, Cantagrel A, et al. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2011; 78:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung CP, Oeser A, Avalos I, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8:R186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eurenius E, Stenström CH. Physical activity, physical fitness, and general health perception among individuals with rheumatoid arthritis. Arthritis Rheum 2005; 53:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roman MJ, Moeller E, Davis A, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006; 144:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Rincón I, Williams K, Stern MP, et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48:1833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kao AH, Wasko MC, Krishnaswami S, et al. C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis. Am J Cardiol 2008; 102:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kao AH, Krishnaswami S, Cunningham A, et al. Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis. J Rheumatol 2008; 35:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           del Rincón I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 2014; 66:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aviña-Zubieta JA, Abrahamowicz M, De Vera MA, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013; 52:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis JM 3rd, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 56:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMahon M, Grossman J, FitzGerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54:2541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charles-Schoeman C, Watanabe J, Lee YY, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009; 60:2870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charles-Schoeman C, Lee YY, Grijalva V, et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 2012; 71:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liao KP, Playford MP, Frits M, et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc 2015; 4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011; 70:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navarro-Millán I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis 2016; 75:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liao KP, Liu J, Lu B, et al. Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients. Arthritis Rheumatol 2015; 67:2004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giles JT, Wasko MCM, Chung CP, et al. Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Associations of Low Circulating Low-Density Lipoprotein Concentration With Subclinical Coronary Atherosclerosis. Arthritis Rheumatol 2019; 71:1426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi W, Kang JH, Park JY, et al. Elevated triglyceride levels are associated with increased risk for major adverse cardiovascular events in statin-naïve rheumatoid arthritis patients: A nationwide cohort study. Semin Arthritis Rheum 2023; 63:152274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giles JT, Sattar N, Gabriel S, et al. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol 2020; 72:31.
          </a>
         </li>
         <li class="breakAll">
          https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing (Accessed on March 04, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           del Rincón I, Polak JF, O'Leary DH, et al. Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann Rheum Dis 2015; 74:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crowson CS, Rollefstad S, Ikdahl E, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2018; 77:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Södergren A, Karp K, Boman K, et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010; 12:R158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raadsen R, Agca R, Boers M, et al. In RA patients without prevalent CVD, incident CVD is mainly associated with traditional risk factors: A 20-year follow-up in the CARRÉ cohort study. Semin Arthritis Rheum 2023; 58:152132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56:2905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Low AS, Symmons DP, Lunt M, et al. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 2017; 76:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas KM, Pace AV, Treharne GJ, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006; 65:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mantel Ä, Holmqvist M, Jernberg T, et al. Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome. Eur Heart J 2015; 36:3413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khandaker MH, Espinosa RE, Nishimura RA, et al. Pericardial disease: diagnosis and management. Mayo Clin Proc 2010; 85:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gravallese EM, Corson JM, Coblyn JS, et al. Rheumatoid aortitis: a rarely recognized but clinically significant entity. Medicine (Baltimore) 1989; 68:95.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7481 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15051620" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11762933" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12628952" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14715346" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14663290" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16793844" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Patterns of cardiovascular risk in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18759273" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19035419" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15693010" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18668561" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19790058" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11953961" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12022343" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10648020" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15642766" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12208376" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19877084" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20506360" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18597411" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20080904" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Role of circulating endothelial progenitor cells in patients with rheumatoid arthritis with coronary calcification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20197563" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Coronary atherosclerosis in rheumatoid arthritis: could endothelial progenitor cells be the missing link?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23095282" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Anti-tumor necrosis factor-αtherapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28992382" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Arterial Inflammation Detected With 18 F-Fluorodeoxyglucose-Positron Emission Tomography in Rheumatoid Arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17116765" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10869258" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17361987" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16947779" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Insulin resistance and impaired beta cell function in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18576352" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31705724" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Coronary Microvascular Dysfunction in Rheumatoid Arthritis Compared to Diabetes Mellitus and Association With All-Cause Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17266963" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16200609" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15529391" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Cardiovascular risk factors in women with and without rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20851020" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17169159" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15696555" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Physical activity, physical fitness, and general health perception among individuals with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16490910" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Preclinical carotid atherosclerosis in patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12847676" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18774002" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18050383" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24504798" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23192907" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17330254" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16868975" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19790070" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22267330" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25637346" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21216812" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25609412" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25917955" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30883031" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Associations of Low Circulating Low-Density Lipoprotein Concentration With Subclinical Coronary Atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37844386" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Elevated triglyceride levels are associated with increased risk for major adverse cardiovascular events in statin-naïve rheumatoid arthritis patients: A nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31469238" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31469238" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24845391" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28877868" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20712865" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36434892" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : In RA patients without prevalent CVD, incident CVD is mainly associated with traditional risk factors: A 20-year follow-up in the CARRÉcohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17763428" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28073800" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16079169" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26400826" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20511488" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Pericardial disease: diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2921941" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Rheumatoid aortitis: a rarely recognized but clinically significant entity.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
